Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Oncolytics reports updated results from U.K. Phase I/II combination REOLYSIN trial at ASCO 2010

Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

7 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

New molecular imaging agent improves diagnosis of recurrent prostate cancer

Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

7 Jun 2010

ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Hiru Corporation and its European subsidiary MindUp BioResearch comment on the recent research findings in the field of cancer treatments for multi-drug resistant non-small cell lung cancer.

4 Jun 2010

American Cancer Society and NPCRC award $1.8M for palliative care research

The American Cancer Society and the National Palliative Care Research Center (NPCRC) are awarding $1.8 million in research grants to researchers at 12 institutions for studies aimed at reducing suffering for seriously ill patients and their family caregivers. The studies will be conducted over the next two years. Since 2007, a collaborative effort by the organizations has awarded 51 grants totaling almost $7 million.

4 Jun 2010

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines addressing ethnicity, gastrointestinal diseases and endoscopic procedures. The guideline suggests that colorectal cancer screening should begin at age 45 for average risk African-American men and women, and that it is recommended that colorectal cancer screening be emphasized for other minority ethnic groups that have lower screening utilization rates.

4 Jun 2010

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

When kidney cancer spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of kidney cancer, specifically renal cell carcinoma, and how patients saw improved prognosis of their cancer.

2 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Cook Medical launches BIGopsy Backloading Biopsy Forceps for accurate diagnosis of kidney cancers

Urologists treating patients with suspicious ureteral or kidney lesions now have a tool to help them more effectively make diagnoses. Cook Medical has introduced the BIGopsy Backloading Biopsy Forceps, a device designed and engineered to obtain large renal or ureteral tissue specimens up to 4 mm3 for cancer diagnosis. The larger sample size helps produce biopsy results without the need for repeat tissue-sampling procedures associated with other biopsy devices.

31 May 2010

Carcinoma News and Research

Further Reading

Oncolytics reports updated results from U.K. Phase I/II combination REOLYSIN trial at ASCO 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

New molecular imaging agent improves diagnosis of recurrent prostate cancer

ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

American Cancer Society and NPCRC award $1.8M for palliative care research

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

Case report on clear cell ICC

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Ablation technique as affective as conventional surgery for treating kidney cancer

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Cook Medical launches BIGopsy Backloading Biopsy Forceps for accurate diagnosis of kidney cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News